New drug SHR-A1904 tested in patients with advanced cancers

NCT ID NCT05277168

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called SHR-A1904 in 83 people with advanced solid tumors, including stomach and pancreatic cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug by IV, and researchers will monitor side effects and any signs of cancer control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A1904 (an experimental drug given by IV)
What this could lead to: If it works, this could point toward a new treatment option for advanced stomach or pancreatic cancers that have stopped responding to other therapies.
What could go wrong: This is an early phase 1/2 trial with only 83 people, so it is too soon to know if the drug is truly effective or safe. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastroesophageal junction adenocarcinoma malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Ajou University Hospital
RECRUITING

Gyeonggi-do, 16499, South Korea
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
CHA Bundang Medical Centre
RECRUITING

Seongnam-si, 13496, South Korea
Central Coast Local Health District
COMPLETED

Gosford, New South Wales, 2250, Australia
Chungbuk National University Hospital
RECRUITING

Cheongju-si, 28644, South Korea
Comprehensive Hematology Oncology
TERMINATED

St. Petersburg, Florida, 33709, United States
Dong-A University Hospital
RECRUITING

Busan, 49201, South Korea
Genesis Care North Shore
COMPLETED

St Leonards, New South Wales, 2065, Australia
Gold Coast Private Hospital
COMPLETED

Southport, Queensland, 4215, Australia
Korea University Anam Hospital
RECRUITING

Seoul, 02841, South Korea
Korea University Guro Hospital
RECRUITING

Seoul, 02841, South Korea
LSU Health Sciences Center
ACTIVE_NOT_RECRUITING

New Orleans, Louisiana, 70112, United States
Macquarie University
COMPLETED

Sydney, New South Wales, 2109, Australia
Mount Sinai Comprehensive Cancer Center
ACTIVE_NOT_RECRUITING

Miami Beach, Florida, 33140, United States
National Institute of Oncology, Arensia Research Clinic
ACTIVE_NOT_RECRUITING

Chisinau, MD-2000, Moldova
One Clinical Research (OCR)
COMPLETED

Nedlands, Western Australia, 8000, Australia
Peninsula and South Eastern Haematology & Oncology Group (PASO)
COMPLETED

Frankston, Victoria, 3199, Australia
Prisma Health
ACTIVE_NOT_RECRUITING

Greenville, South Carolina, 29605, United States
Rhode Island Hospital
TERMINATED

Providence, Rhode Island, 02905, United States
Samsung Medical Center
RECRUITING

Seoul, 06531, South Korea
Scientia Clinical Research Ltd
COMPLETED

Randwick, New South Wales, 2031, Australia
Seoul National University Bundang Hospital
RECRUITING

Seongnam, KS009, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 3080, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
Sydney South West Private Hospital
COMPLETED

Liverpool, New South Wales, Australia
The University of Texas MD Anderson Cancer Center
ACTIVE_NOT_RECRUITING

Houston, Texas, 77030, United States
University Hospitals Cleveland Medical Center
TERMINATED

Cleveland, Ohio, 44106, United States
Westmead Hospital
COMPLETED

Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.